Drug Trial Radar · NCT05826990
A Study to Investigate PK, Safety, Tolerability of Cefepime-enmetazobactam in Pediatric Participants With cUTI
Last checked: Nov 20, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Sep 11, 2023
Primary completion
May 21, 2029
Study completion May 21, 2029
Sponsor
- Lead sponsor
- Orchid Pharma Europe GmbHIndustry
- Sponsor type
- Industry
- Collaborators
- Innvocept Global Solutions Private Limited
- First posted
- Apr 24, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase 2 study is part of regulatory commitments in the United States (PSP) and Europe (PIP) to evaluate cefepime-enmetazobactam in paediatric participants with cUTI to support extension of the indication for cefepime-enmetazobactam to children with cUTI.
Conditions
- Complicated Urinary Tract Infection
Interventions
cefepime and enmetazobactam combinationDrug
Cefepime and enmetazobactam fixed dose combination administered intravenously every 8 hours as single drug formulation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics CmaxTime frame: Day 1 - Day 2
- Pharmacokinetics TmaxTime frame: Day 1 - Day 2
- Pharmacokinetics AUC0-tauTime frame: Day 1 - Day 2
- Pharmacokinetics AUC0-infTime frame: Day 1 - Day 2
- Pharmacokinetics t1/2Time frame: Day 1 - Day 2
- Pharmacokinetics CL & VdTime frame: Day 1 - Day 2
- Pharmacokinetics CminTime frame: Day 1 - Day 2
- Safety and TolerabilityTime frame: before 1st study intervention until EOT +28 Days (±5 Days)
- Safety and TolerabilityTime frame: before 1st study intervention until EOT +28 Days (±5 Days)
- Safety and TolerabilityTime frame: before 1st study intervention until EOT +28 Days (±5 Days)
- Safety and TolerabilityTime frame: before 1st study intervention until EOT +28 Days (±5 Days)
- Safety and TolerabilityTime frame: before 1st study intervention until EOT +28 Days (±5 Days)
Locations
8 sites in 6 countries. Site status is shown where the registry gives one.
Fakultní nemocnice Hradec Králové -Ústav klinické biochemie a diagnostiky
Hradec Králové, Czechia · Withdrawn
Oblastni nemocnice Kolin, a.s., nemocnice Stredoceskeho kraje - Detske oddeleni
Kolín, Czechia · Recruiting
Hopital des Enfants
Toulouse, France · Withdrawn
Debreceni Egyetem Klinikai Központ Gyermekgyógyászati Klinika
Debrecen, Hungary · Withdrawn
Kanizsai Dorottya Hospital
Nagykanizsa, Hungary · Recruiting
SZPZOZ im. Dzieci Warszawy w Dziekanowie Leśnym
Łomianki, Poland · Recruiting
Národný ústav detských chorôb (NÚDCH)
Bratislava, Slovakia · Recruiting
Hospital Universitario La Paz
Madrid, Spain · Withdrawn
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.